Table 2.

Pharmacokinetic parameters of formulations.

Group		AUC(0–60 min)a (µg/ml/min)	MRT(0–60)b (min)
1st dose	1%GE	1224.44 ± 24.65	10.93 ± 1.23
	3%GE	1746.27 ± 22.83	11.83 ± 0.96
	9%GE	2201.15 ± 27.37	12.47 ± 1.54
	9%PE	5723.06 ± 85.14	25.30 ± 2.83
	1%HE	1107.47 ± 21.28	10.13 ± 0.78
2nd dose (9%PE)	Pretreated with 1%GE-B	1236.65 ± 27.23	19.45 ± 1.54
	Pretreated with 3%GE-B	2081.18 ± 28.44	22.48 ± 2.12
	Pretreated with 9%GE-B	2712.66 ± 22.56	23.49 ± 2.76
	Pretreated with 9%PE-B	204.15 ± 9.38	9.92 ± 0.73
	Pretreated with 1%HE-B	5593.62 ± 84.23	24.94 ± 2.31
3rd dose (9%PE)	Pretreated with 1%GE-B then AD treatment	5023.59 ± 86.75	22.01 ± 2.28
	Pretreated with 3%GE-B then AD treatment	5423.86 ± 78.48	23.98 ± 2.54
	Pretreated with 9%GE-B then AD treatment	5323.08 ± 82.83	23.25 ± 3.05
	Pretreated with 5%Glu-B then AD treatment	5642.75 ± 85.37	24.68 ± 2.83

^aAREA under curve from time 0 to 60 min.

^bThe mean retention time from time 0 to 60 min.